Pfizer’s Growth Potential in Obesity Treatment Amid Financial Constraints Justifies Hold Rating

Courtney Breen, an analyst from Bernstein, maintained the Hold rating on Pfizer. The associated price target remains the same with $30.00.

Courtney Breen’s rating is based on several factors, including Pfizer’s recent guidance and management call insights. The company has provided new information on its obesity treatment developments, highlighting the timing for additional data and its plans for clinical trials. This indicates a potential for growth in this segment, although the full impact is yet to be realized.
Additionally, Pfizer’s management has offered more clarity on the trajectory of key financial components, such as margins and spending, with an expected return to growth not anticipated until after 2029. While the hospital business unit’s restructuring and capital allocation priorities, like pipeline investments and M&A, are positive steps, they also highlight the limitations in Pfizer’s current financial flexibility. Overall, while the call was positive, it underscores the constraints and extended timeline for Pfizer’s recovery, justifying the Hold rating.

According to TipRanks, Breen is a 4-star analyst with an average return of 18.5% and an 89.19% success rate. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Moderna.

In another report released yesterday, J.P. Morgan also maintained a Hold rating on the stock with a $30.00 price target.